Industry Partners.

EasyM™ has been demonstrated to be an effective MRD assay for patients undergoing treatment for Multiple Myeloma in the clinic.

The achievement of MRD negativity is strongly correlated with Progression Free Survival (PFS)1,2.

EasyM has been demonstrated to be an effective MRD assay for patients undergoing treatment for Multiple Myeloma in the clinic. The achievement of MRD negativity is strongly correlated with Progression Free Survival (PFS) and meets the criteria for PFS surrogacy.

Consider including EasyM™ for improved disease monitoring in upcoming clinical trials for Multiple Myeloma therapies. EasyM™ can provide:

  1. Fast and reliable way to assess treatment efficacy
  2. Ease of recruitment into the trial and better compliance without the need for bone marrow aspirations
  3. Non-invasive testing in peripheral blood enables more frequent disease monitoring
  4. Validated and standardized testing at a CLIA certified central laboratory
  5. An ideal complement to other MRD assays for a more accurate MRD status

Please contact us to explore how to include EasyM™ into your clinical trials.

1. Landgren, O. et al. Bone Marrow Transplant. (2016) 51:1565– 8.

2. Kaddoura, M. et al. Am J Hematol. 2022; 97(3): 267- 273